TY - JOUR
T1 - N-hydroxypyrazolyl glycine derivatives as selective N-methyl-D-aspartic acid receptor ligands
AU - Clausen, Rasmus P.
AU - Christensen, Caspar
AU - Hansen, Kasper B.
AU - Greenwood, Jeremy R.
AU - Jørgensen, Lars
AU - Micale, Nicola
AU - Madsen, Jens Christian
AU - Nielsen, Birgitte
AU - Egebjerg, Jan
AU - Bräuner-Osborne, Hans
AU - Traynelis, Stephen F.
AU - Kristensen, Jesper L.
PY - 2008/7/24
Y1 - 2008/7/24
N2 - A series of analogues based on N-hydroxypyrazole as a bioisostere for the distal carboxylate group of aspartate have been designed, synthesized, and pharmacologically characterized. Affinity studies on the major glutamate receptor subgroups show that these 4-substituted N-hydroxypyrazol-5-yl glycine (NHP5G) derivatives are selectively recognized by N-methyl-D-aspartic acid (NMDA) receptors and that the (R)-enantiomers are preferred. Moreover, several of the compounds are able to discriminate between individual subtypes among the NMDA receptors, providing new pharmacological tools. For example, 4-propyl NHP5G is an antagonist at the NR1/NR2A subtype but an agonist at the NR1/NR2D subtype. Molecular docking studies indicate that the substituent protrudes into a region that may be further exploited to improve subtype selectivity, thereby opening up a design strategy for ligands which can differentiate individual NMDA receptor subtypes.
AB - A series of analogues based on N-hydroxypyrazole as a bioisostere for the distal carboxylate group of aspartate have been designed, synthesized, and pharmacologically characterized. Affinity studies on the major glutamate receptor subgroups show that these 4-substituted N-hydroxypyrazol-5-yl glycine (NHP5G) derivatives are selectively recognized by N-methyl-D-aspartic acid (NMDA) receptors and that the (R)-enantiomers are preferred. Moreover, several of the compounds are able to discriminate between individual subtypes among the NMDA receptors, providing new pharmacological tools. For example, 4-propyl NHP5G is an antagonist at the NR1/NR2A subtype but an agonist at the NR1/NR2D subtype. Molecular docking studies indicate that the substituent protrudes into a region that may be further exploited to improve subtype selectivity, thereby opening up a design strategy for ligands which can differentiate individual NMDA receptor subtypes.
UR - http://www.scopus.com/inward/record.url?scp=47849098514&partnerID=8YFLogxK
U2 - 10.1021/jm800025e
DO - 10.1021/jm800025e
M3 - Article
C2 - 18578474
AN - SCOPUS:47849098514
SN - 0022-2623
VL - 51
SP - 4179
EP - 4187
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 14
ER -